Literature DB >> 10817792

TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis.

P D Arkwright1, S Laurie, M Super, V Pravica, M J Schwarz, A K Webb, I V Hutchinson.   

Abstract

BACKGROUND: Polymorphisms in transforming growth factor (TGF)-beta(1) associated with variations in cytokine levels are linked to fibrosis in a number of tissues. However, the contribution of this cytokine to organ fibrosis in patients with cystic fibrosis is presently unclear. This study was undertaken to examine the association between TGF-beta(1) gene polymorphisms and the development of pulmonary dysfunction in patients with cystic fibrosis.
METHODS: Polymorphisms in the TGF-beta(1) gene defining amino acids of codons 10 and 25 were determined by ARMS-PCR using DNA stored on 171 Caucasian patients who were homozygous for the DeltaF508 mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clinical information on the patients was obtained from medical records.
RESULTS: Patients with cystic fibrosis of a TGF-beta(1) high producer genotype for codon 10 had more rapid deterioration in lung function than those with a TGF-beta(1) low producer genotype. The relative risk of accelerated decline in forced expiratory volume in one second (FEV(1)) to 50% predicted and forced vital capacity (FVC) to 70% predicted of patients with a high producer genotype was 1.74 (95% CI 1.11 to 2. 73) compared with 1.95 (95% CI 1.24 to 3.06) for those with a low producer genotype. DISCUSSION: TGF-beta(1) genotypes may have a role in mediating pulmonary dysfunction in patients with cystic fibrosis. Further work is required to determine whether inhibition of TGF-beta(1) activity in these patients may slow disease progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817792      PMCID: PMC1745768          DOI: 10.1136/thorax.55.6.459

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms.

Authors:  C Perrey; S J Turner; V Pravica; W M Howell; I V Hutchinson
Journal:  Transpl Immunol       Date:  1999-06       Impact factor: 1.708

2.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix.

Authors:  R A Ignotz; J Massagué
Journal:  J Biol Chem       Date:  1986-03-25       Impact factor: 5.157

3.  TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis.

Authors:  S Kanzler; A W Lohse; A Keil; J Henninger; H P Dienes; P Schirmacher; S Rose-John; K H zum Büschenfelde; M Blessing
Journal:  Am J Physiol       Date:  1999-04

4.  Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation.

Authors:  A J Franko; J Sharplin; A Ghahary; M H Barcellos-Hoff
Journal:  Radiat Res       Date:  1997-02       Impact factor: 2.841

5.  Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.

Authors:  J B Kopp; V M Factor; M Mozes; P Nagy; N Sanderson; E P Böttinger; P E Klotman; S S Thorgeirsson
Journal:  Lab Invest       Date:  1996-06       Impact factor: 5.662

6.  Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders.

Authors:  B Corrin; D Butcher; B J McAnulty; R M Dubois; C M Black; G J Laurent; N K Harrison
Journal:  Histopathology       Date:  1994-02       Impact factor: 5.087

7.  Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity.

Authors:  E M Bayer; W Herr; S Kanzler; C Waldmann; K H Meyer Zum Büschenfelde; H P Dienes; A W Lohse
Journal:  J Hepatol       Date:  1998-05       Impact factor: 25.083

Review 8.  Cystic fibrosis: genotypic and phenotypic variations.

Authors:  J Zielenski; L C Tsui
Journal:  Annu Rev Genet       Date:  1995       Impact factor: 16.830

9.  Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction.

Authors:  A B Roberts; L C Lamb; D L Newton; M B Sporn; J E De Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Lung cytokine production in bleomycin-induced pulmonary fibrosis.

Authors:  S H Phan; S L Kunkel
Journal:  Exp Lung Res       Date:  1992 Jan-Mar       Impact factor: 2.459

View more
  63 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 2.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

3.  DNA: where to now?

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2007-05

4.  Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.

Authors:  Michael D Kim; Nathalie Baumlin; Makoto Yoshida; Deepika Polineni; Sebastian F Salathe; Joseph K David; Charles A Peloquin; Adam Wanner; John S Dennis; Juliette Sailland; Philip Whitney; Frank T Horrigan; Juan R Sabater; William M Abraham; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

5.  Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms.

Authors:  Riddhish Shah; Brad Rahaman; Carolyn Katovich Hurley; Phillip E Posch
Journal:  Hum Genet       Date:  2005-12-14       Impact factor: 4.132

6.  Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Authors:  Heike Labenski; Silke Hedtfeld; Tim Becker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

Review 7.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

9.  Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.

Authors:  Olivera Tarabar; Bojana Cikota-Aleksić; Ljiljana Tukić; Nenad Milanović; Aleksandar Aleksić; Zvonko Magić
Journal:  Int J Clin Oncol       Date:  2013-03-27       Impact factor: 3.402

10.  Complex two-gene modulation of lung disease severity in children with cystic fibrosis.

Authors:  Ruslan Dorfman; Andrew Sandford; Chelsea Taylor; Baisong Huang; Daisy Frangolias; Yongqian Wang; Richard Sang; Lilian Pereira; Lei Sun; Yves Berthiaume; Lap-Chee Tsui; Peter D Paré; Peter Durie; Mary Corey; Julian Zielenski
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.